Hutch Director Dr. Lee Hartwell To Share His Vision Of Biotechnology In The 21st Century At BIO '99 Meeting

May 11, 1999

Conference also to feature talks by three other Hutch scientists: Where will biotechnology be in the year 2050? How will it affect our lives? What technologies will most influence our future research direction? How will these changes affect the development of new drugs and other products?

Dr. Lee Hartwell, president and director of the Fred Hutchinson Cancer Research Center, will join four other biotechnology leaders in addressing such questions during a symposium entitled "Visions of Biotechnology Pioneers" from 8 to 9:30 a.m. Monday, May 17. The symposium is part of BIO '99, an international biotechnology meeting and exhibition to be held May 16 to 20 at the Washington State Convention and Trade Center in Seattle.

Hartwell is a recipient of the prestigious Albert Lasker Basic Medical Research Award and is internationally known for his work in yeast genetics.

Joining Hartwell in addressing the future of biotechnology will be the University of Washington's Dr. Edwin Krebs, 1992 recipient of the Nobel Prize for Physiology in Medicine; Dr. George Rathmann, founder and former president and CEO of Amgen; the University of British Columbia's Michael Smith, 1993 Nobel Prize recipient in chemistry; and Dr. Kathryn Zoon, director of the Center for Biologics Evaluation and Research at the U.S. Food and Drug Administration. The symposium will be moderated by KCTS-TV business analyst Barry Mitzman.

From 9:30 to 11:15 a.m. the same day, three Hutchinson Center scientists will participate in a technology-transfer forum that will present leading candidate technologies from 20 top research institutions.

Presenting from the Hutch will be: The BIO '99 meeting is expected to draw an estimated 5,000 biotechnology industry leaders from 40 nations, including representatives from many of Washington's 120 biotechnology and medical-device companies.

More than 500 experts will speak in 125 scientific, business and governmental policy workshops and seminars.
-end-
For registration information, check the Biotechnology Industry Organization Web site: www.bio.org.

To schedule an interview with participating Hutch scientists, contact Kristen Woodward at 206-667-5095.



Fred Hutchinson Cancer Research Center

Related Leukemia Articles from Brightsurf:

New therapeutic approach against leukemia
Using an RNA molecule complex, researchers can prevent retention of cancer stem cell in their tumor supporting niche

Nanoparticle for overcoming leukemia treatment resistance
One of the largest problems with cancer treatment is the development of resistance to anticancer therapies.

Key gene in leukemia discovered
Acute myeloid leukemia (AML) is one of the most common forms of blood cancer among adults and is associated with a low survival rate, and leads to the inhibition of normal blood formation.

Vitamin B6, leukemia's deadly addiction
Researchers from CSHL and Memorial Sloan Kettering Cancer Center have discovered how Acute Myeloid Leukemia is addicted to vitamin B6.

Artificial intelligence tracks down leukemia
Artificial intelligence can detect one of the most common forms of blood cancer - acute myeloid leukemia -- with high reliability.

Milestone reached in new leukemia drug
Using a chemical compound called YKL-05-099, a team of cancer researchers from CSHL and the Dana Farber Institute was able to target the Salt-Inducible Kinase 3 (SIK3) pathway and extend survival in mice with MLL leukemia.

The drug combination effective against bovine leukemia
Scientists have succeeded in reducing levels of the bovine leukemia virus (BLV) in cows with severe infections by combining an immune checkpoint inhibitor and an enzyme inhibitor.

Towards a safer treatment for leukemia
An international team of researchers at VIB-KU Leuven, Belgium, the UK Dementia Institute and the Children's Cancer Institute, Australia, have found a safer treatment for a specific type of leukemia.

Research paves way for new source for leukemia drug
Chemistry researchers have patented a method for making anti-leukemia compounds that until now have only been available via an Asian tree that produces them.

An atlas of an aggressive leukemia
A team of researchers led by Bradley Bernstein at the Ludwig Center at Harvard has used single-cell technologies and machine learning to create a detailed 'atlas of cell states' for acute myeloid leukemia (AML) that could help improve treatment of the aggressive cancer.

Read More: Leukemia News and Leukemia Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.